Yasser A. Abd El-Hady

Yasser A. Abd El-Hady

Auto-generated profile, based on publicly available information

Yasser A. Abd El-Hady

Faculty of Medicine, Beni Suef University, Beni Suef 62511, Egypt

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2012 in European Heart Journal - Cardiovascular Imaging
Verified
Journal Article
Open access
PDF file
SKSebastiaan A. Kleijn
Sebastiaan A. Kleijn
MAMohamed Fa. Aly
Mohamed Fa. Aly
DKDirk L. Knol
Dirk L. Knol
CTCaroline B. Terwee
Caroline B. Terwee
EJElise P. Jansma
Elise P. Jansma
OKOtto Kamp
Otto Kamp
In a time of controversy regarding the use of echocardiography for assessment of left ventricular (LV) dyssynchrony and prediction of response to cardiac resynchronization therapy (CRT), this meta-analysis aimed to evaluate the feasibility and reliability of LV dyssynchrony assessment by three-dimensional echocardiography (3DE), determine clinically useful reference values in healthy subjects and heart failure patients, and examine the accuracy of 3DE to predict response to CRT. A total of 73 studies that evaluated the assessment of LV dyssynchrony by 3DE were eligible. The systolic dyssynchrony index (SDI) for 16 segments, being the predominant 3DE dyssynchrony parameter, was used for data pooling. Results demonstrated that LV dyssynchrony assessment by 3DE is feasible in 94% of studied subjects [95% confidence interval (CI): 92–95%)]. Pooled estimates of intraclass correlation coefficients (ICC) and limits of agreement (LoA) demonstrated that SDI has good interobserver (ICC: 0.92, LoA: 4.07%) and intraobserver reliability (ICC: 0.95, LoA: 2.10%). Reference values of SDI in healthy subjects, heart failure patients in general, and patients eligible for CRT were 2.7 ± 0.9%, 9.8 ± 3.9%, and 10.7 ± 3.6%, respectively. Meta-regression analysis demonstrated that reference values of SDI in healthy subjects significantly differed between different software [1.80% (95% CI: 0.55–3.05%), P< 0.001]. In patients eligible for CRT, SDI had good accuracy to predict treatment response with a weighted mean cut-off value of 9.8% and pooled estimates for sensitivity and specificity of 93% (95% CI: 89–97%) and 75% (95% CI: 58–93%), respectively. 3DE is a feasible and reliable tool for assessment of LV dyssynchrony and may have additional value to current selection criteria for accurate prediction of response to CRT.

25 October 2024 in Cardiology and Therapy
Verified
Journal Article
Open access
PDF file
MSMohamed Sobhy
Mohamed Sobhy
AEAdel Eletriby
Adel Eletriby
HRHany Ragy
Hany Ragy
HKHossam Kandil
Hossam Kandil
MSMohamed Ayman Saleh
Mohamed Ayman Saleh
YAYasser Abdelhady
Yasser Abdelhady
Introduction The renin–angiotensin–aldosterone system (RAAS) plays a pivotal role in regulating blood pressure (BP), with dysregulation of RAAS resulting in hypertension and potentially heart failure (HF), myocardial infarction (MI), cardio-renal syndrome, and stroke. RAAS inhibitors, such as angiotensin-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs), have advantages beyond BP control. However, differences between these two drug classes need to be considered when choosing a therapy for preventing cardiovascular events. Methods A panel of 36 Egyptian cardiologists developed consensus statements on RAAS inhibitors for primary and secondary prevention of cardiovascular outcomes and stroke, using a modified three-step Delphi process. Results The consensus statements highlight the importance of effective BP control and the role of RAAS blockade for prevention and management of various cardiovascular diseases. ACEis and ARBs differ in their mode of action and, thus, clinical effects. On the basis of available evidence, the consensus group recommended the following: ACEis should be considered as first choice (in preference to ARBs) to reduce the risk of MI, for primary prevention of HF, and for secondary prevention of stroke. ACEis and ARBs show equivalent efficacy for the primary prevention of stroke. Evidence also favors the preferential use of ACEis in patients with type 2 diabetes, for BP control, for the primary prevention of diabetic kidney disease, and to reduce the risk of major cardiovascular and renal outcomes. Treatment with an ACEi should be started within 24 h of ST segment elevation MI (and continued long term) in patients with HF, left ventricular systolic dysfunction, and/or diabetes. Angiotensin receptor/neprilysin inhibitors (ARNIs) are the first choice for patients with HF and reduced ejection fraction, with ACEis being the second choice in this group. ARBs are indicated as alternatives in patients who cannot tolerate ACEis. ACEis may be associated with cough development, but the incidence tends to be overestimated, and the risk can be reduced by use of a lipophilic ACEi or combining the ACEi with a calcium channel blocker. Conclusion RAAS blockade is an essential component of hypertension therapy; however, the protective effects provided by ACEis are superior to those of ARBs. Therefore, an ACEi is indicated in almost all cases, unless not tolerated.

1 July 2020 in The Egyptian Heart Journal
Verified
Journal Article
Open access
PDF file
SSSameh Shaheen
Sameh Shaheen
AWAhmad Wafa
Ahmad Wafa
MMMostafa Mokarab
Mostafa Mokarab
BZBassem Zarif
Bassem Zarif
ABAhmed Bendary
Ahmed Bendary
MYMahmoud Youssef
Mahmoud Youssef
Background: Apart from few small single-center studies, there are limited data about STEMI patients in Egypt. Nineteen Egyptian centers (with and without PCI facilities) participated in this registry with 1356 patients who were compared to 7420 patients from other ESC countries. The aims of this study were to describe the characteristics of patients with STEMI, to assess STEMI management patterns particularly the current use of reperfusion therapies, to evaluate the organization of STEMI networks across Egypt, to evaluate in-hospital patient outcome, and to compare Egyptian patients with other ESC countries. Results: Compared to other ESC countries, Egyptian patients were younger (mean age 55.4 ± 11.3 vs. 62.9 ± 12.4; p < 0.001 and 4.36% vs. 19.41%% were ≥ 75 years old; p < 0.001) with fewer females (18.44% vs. 25.63%; p < 0.001). Egypt had longer median time between symptoms onset and first medical contact: 120.0 (60.0; 240.0) vs.100.0 (50.0; 240.0) p < 0.001. Self-presentation rather than EMS presentation was the mode of admission in 86.06% in Egypt vs. 25.83% in EU countries (p < 0.001). On qualifying ECG, anterior STEMI was in 57.08% in Egypt vs. 45.98% in other countries (p < 0.001). Initial reperfusion therapy was 49.12%, 43.07%, and 7.26% for primary PCI, thrombolytic therapy and no reperfusion in Egypt vs. 85.42%, 7.26%, and 7.82% for EU countries, respectively. In-hospital mortality was 4.65% in Egypt vs. 3.50% in other countries p 0.040 and was 18.87% in no reperfusion vs. 2.10% in primary PCI vs. 4.97% in thrombolysis (p < 0.001) among Egyptians. Patients were discharged on aspirin in 98.61%, clopidogrel in 91.07%, ticagrelor in 7.31%, DAPT in 97.69%, beta blockers in 82.83%, ACE inhibitors in 84.76%, MRAs in 10.01%, and statins in 99.77%. Conclusion: Compared to other ESC countries, Egyptian STEMI patients were younger, more frequently current smokers and diabetics, and had longer time between symptoms onset and first medical contact with more self-presentation rather than EMS presentation. Thrombolytic therapy is still a common reperfusion therapy in Egypt while primary PCI was offered to half of the patients. In-hospital mortality was significantly higher in Egypt and was highest among no reperfusion patients and lowest among PPCI patients.

30 October 2012 in European Heart Journal - Cardiovascular Imaging
Verified
Journal Article
Open access
PDF file
MAMohamed F.A. Aly
Mohamed F.A. Aly
SKSebastiaan A. Kleijn
Sebastiaan A. Kleijn
KBKarin de Boer
Karin de Boer
YEYasser A. Abd El-Hady
Yasser A. Abd El-Hady
KSKhalid A. Sorour
Khalid A. Sorour
OKOtto Kamp
Otto Kamp
We directly compared TomTec and QLAB software packages for the three-dimensional echocardiographic (3DE) assessment of left ventricular (LV) dyssynchrony including their ability to predict response to cardiac resynchronization therapy (CRT) in patients with ischaemic and non-ischaemic cardiomyopathy. A total of 140 heart failure patients with the LVEF ≤35% and 60 healthy volunteers underwent 3DE. A subgroup of 60 patients underwent CRT and were evaluated before and 6–12 months after implantation. The systolic dyssynchrony index (SDI) was derived from the dispersion of time to minimum regional volume for all 16 LV segments and measured with both software packages and compared using Pearson's correlation and Bland–Altman analysis. Measurements of SDI were significantly higher using TomTec compared with QLAB in both patients (10.9 ± 3.8 vs. 9.7 ± 3.9, P < 0.001) and healthy volunteers (4.1 ± 0.8 vs. 2.4 ± 1, P < 0.001), with large biases and wide limits of agreement. A moderate correlation (r = 0.65, P < 0.001) was observed between both software packages in patients while their inter-observer and intra-observer reliability were good. Of the 60 patients undergoing CRT, reverse remodelling as a measure of response was observed in 41 patients (68%). The optimal SDI cut-off value to predict response to CRT was higher for TomTec than for QLAB (8.8 vs.7.3%, P < 0.001) and demonstrated better sensitivity and specificity (93 and 61%, respectively) compared with QLAB (88 and 33%, respectively). Response prediction in patients with non-ischaemic cardiomyopathy was excellent with a sensitivity and specificity of 95 and 100% for TomTec and 70 and 83% for QLAB using similar cut-off values of 9.1 and 9.2%, respectively. Different 3DE software packages for the assessment of mechanical dyssynchrony should not be used interchangeably until better software standardization is achieved. Dyssynchrony assessment with 3DE for the prediction of response to CRT seems particularly useful in patients with non-ischaemic cardiomyopathy.

29 December 2019 in The Egyptian Heart Journal
Verified
Journal Article
Open access
PDF file
OAOsama Ahmed Amin
Osama Ahmed Amin
YHYasser Ahmed Abdel Hady
Yasser Ahmed Abdel Hady
MEMohammad Ahmad Nour El-Din Esmail
Mohammad Ahmad Nour El-Din Esmail
Background: The aim of our work was to compare the myocardial perfusion imaging by single-photon emission tomography (MPI-SPECT) as a non-invasive, relatively non-expensive test versus the instantaneous wave-free ratio (IFR) for the evaluation of functional significance of the borderline coronary artery lesions in the view of results of fractional flow reserve (FFR) which is considered the gold standard reference test. Results: Our study was conducted in the Cardiology Department. It included 50 patients with borderline coronary artery lesions; they underwent physiological evaluation by stress/rest myocardial perfusion imaging using followed by an invasive physiological assessment by Instantaneous wave-free ratio (IFR) and Fractional flow reserve (FFR). Finally, the results of both SPECT MPI and IFR were compared to FFR as a gold standard reference. There was a strong (kappa = 0.754) significant (P value < 0.001) agreement between the MPI results and FFR results and the overall agreement was 88%. The sensitivity of the MPI was 81.8%, the specificity was 92.9%, the positive predictive value was 90%, the negative predictive value was 86.7%, the positive likelihood ratio was 11.45, and the negative likelihood ratio was 0.20. There was a strong (kappa = 0.918) significant (P value < 0.001) agreement between the IFR results and FFR results and the overall agreement was 96%. The sensitivity of the IFR was 90.9%, the specificity was 100%, the positive predictive value was 100 %, the negative predictive value was 93.3%, and the negative likelihood ratio was 0.09. Conclusions: The instantaneous wave-free ratio (IFR) may be a valid alternative to fractional flow reserve to assess the functional significance of intermediate coronary lesions. The myocardial perfusion imaging may be an alternative, non-invasive, relatively non-expensive test for the evaluation of the physiological significance of intermediate coronary lesions.

30 September 2026 in Medical Sciences
Verified
Journal Article
Open access
PDF file
MSMohamed Sobhy
Mohamed Sobhy
MEMohamed Fahmy Elnoamany
Mohamed Fahmy Elnoamany
MLMohamed Loutfi
Mohamed Loutfi
SMSharaf Eldeen Mahmoud
Sharaf Eldeen Mahmoud
MGMohamed Abdel Ghany
Mohamed Abdel Ghany
YAYasser A. Abdelhady
Yasser A. Abdelhady
Background/Objectives: Stable angina is a significant health issue in Egypt, often showing poor responses to standard treatments. This study examines the effectiveness and safety of early combination therapy with trimetazidine and either a β-blocker or a calcium channel blocker (CCB) among Egyptian patients with stable angina. Methods: This sub-analysis of the Egyptian cohort from the COMBINE Angina study included patients with stable angina (CCS class II–III) who remained symptomatic after 2–4 weeks of β-blocker or CCB monotherapy. Patients received trimetazidine 35 mg modified-release twice daily as an add-on treatment for 4 months. The primary outcome was the Seattle Angina Questionnaire (SAQ-7) summary score, with secondary outcomes including SAQ-7 domain scores, CCS class, frequency of angina attacks, nitrate use, treatment satisfaction, adherence, and safety. Results: In the global COMBINE study involving 578 patients, the Egyptian cohort had 138 participants with an average age of 58.3 years. The SAQ-7 summary score improved from 42.2 at baseline to 76.8 at month 4 (mean change 34.6 points, 95% CI 31.3 to 38.0; p < 0.0001). All 138 patients contributed data at every visit for the SAQ-7 summary score. Patients in CCS class I increased from 0% to 56.5%, weekly angina attacks fell from 5.0 to 1.7 (p < 0.0001), and short-acting nitrate use decreased from 2.9 to 1.0 doses per week (p < 0.0001). Patient satisfaction was about 75%, and physician satisfaction reached 83% by month 4. Medication adherence also improved (MARS-5 score: 20.8 to 22.7), and two non-serious, treatment-related adverse events (nausea and somnolence) were reported in a single patient (0.7%), with no serious or fatal events. Conclusions: In Egyptian patients with stable angina, implementing an early combination strategy incorporating trimetazidine with first-line β-blocker or CCB therapy was associated with clinically meaningful improvements in angina symptoms, functional status, and quality of life, with good tolerability and high satisfaction. As the study was observational and single-arm, these findings are provisional and require confirmation in further long-term controlled studies.